Peltola H, Case S, Perri S F, Siddiqui W A
Scand J Infect Dis. 1983;15(4):383-9. doi: 10.3109/inf.1983.15.issue-4.09.
Six Aotus trivirgatus monkeys were included in a clinical study to compare the adverse reactions caused by a Plasmodium falciparum antigen and 2 adjuvants, a lipoidal amine, CP-20,961, and a muramyl dipeptide derivative, [B30]-MDP. Two monkeys were given 2 intramuscular injections, 3 weeks apart, of 1 of these vaccine components. Both the antigen and the two adjuvants caused local and general reactions as well as hematological and biochemical changes. Except for an up to 60% rise in leukocyte count, the antigen caused reactions least, followed by [B30]-MDP. CP-20,961 evoked more vigorous reactions and changes, but none of them reached such an extent that it would contraindicate its potential use in forthcoming vaccine studies. We conclude that both adjuvants are to be considered as relatively safe when combined with an appropriate P. falciparum antigen.
六只三带松鼠猴被纳入一项临床研究，以比较恶性疟原虫抗原和两种佐剂（一种脂胺CP-20961和一种胞壁酰二肽衍生物[B30]-MDP）所引起的不良反应。给两只猴子每隔3周进行两次肌肉注射，每次注射其中一种疫苗成分。抗原和两种佐剂均引起了局部和全身反应以及血液学和生化变化。除白细胞计数最多升高60%外，抗原引起的反应最小，其次是[B30]-MDP。CP-20961引起的反应和变化更为强烈，但均未达到会妨碍其在未来疫苗研究中潜在应用的程度。我们得出结论，当与合适的恶性疟原虫抗原联合使用时，这两种佐剂都被认为相对安全。
